The guidelines rank Standard as the strongest statement, followed by Recommended and Option. Standard means the benefits outweigh the risks.
This retrospective cohort study (N=103,250) used data from the IMS LifeLink Health Plan Claims Database. Eligible patients were men and women ≥18 years of age with a diagnosis of OAB, an index prescription (first documentation of a prescription) for an AC between July 2005 and June 2008, and a follow-up period of 24 months. Treatment failure was defined as discontinuing an AC therapy or switching to another AC. Discontinuation was defined as a treatment gap of ≥45 days.2
According to 2 separate surveys, the top reasons that OAB patients discontinued ACs were poor tolerability and/or lack of efficacy.3,4BOTOX® can help4 Learn How ►
Offers up to ~3x Better Efficacy vs Placebo at Week 12
Significant reduction in mean daily urinary incontinence episodes at week 12 shown in 2 studies5
Mean change from baseline in daily frequency of UI episodes at week 12 in study 1 was 45% with BOTOX® (n = 278) vs 18% with placebo (n = 272); in study 2, 55% with BOTOX® (n = 275) vs 19% with placebo (n = 269). Mean baseline daily frequency of UI episodes: study 1, BOTOX® = 5.5/day and placebo = 5.1/day; study 2, BOTOX® = 5.5/day and placebo = 5.7/day (P<.001 vs placebo).5